Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study

Tayibe Bal; Hasibullah Yaqoobi; Yusuf Önlen; Mehmet Çabalak; Serdar Doğan

Makale detayları

Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study

Yazarlar:

Tayibe Bal | Hasibullah Yaqoobi | Yusuf Önlen | Mehmet Çabalak | Serdar Doğan

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 2, pp.16-21

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001295731

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objective: This study aimed to examine whether there is a difference in the level of immune response against hepatitis A virus between patients with and without COVID-19 infection. Materials and Methods: Fifty patients with COVID-19 disease confirmed by PCR positivity who were followed in our clinic between 1 June 2020 and 1 September 2020 were enrolled in this cross-sectional, retrospective, single-center study. A total of 150 patients, who had similar demographic characteristics and were randomly selected among the patients who Anti HAV IgG levels were determined during their admission to our clinic in the last two years before the pandemic November 1, 2017-November 1, 2019 were taken as the control group. Anti-HAV IgG seropositivity rates and serum antibody titers were compared between these two groups. Results: The median age of the 200 cases was 48.5 25.-75.Quartiles43.0-59.0 years, 108 54 were male and 92 46 were female. One hundred, and forty-two of the cases were 60 years and above, but the proportion of the patients aged 60 and over in the patient groups was similar p0.105. Although anti-HAV IgG seropositivity rates in COVID-19 patients were similar to cases in the control group p0.062, anti-HAV IgG titers in COVID-19 cases were found to be significantly lower than in control patients p0.001. Anti-HAV IgG titers were found to be significantly lower in critical COVID-19 patients n7 compared to other COVID-19 patients n43, p0.049. In addition, it was observed that there was a significant and strong correlation between the anti-HAV IgG titer and the presence of critical COVID-19 disease η0.988. Conclusion: Although our results seem to support the thesis that the presence of HAV vaccine or previous HAV infection may be protective against COVID- 19 infection, especially in terms of preventing critical disease course, prospective studies with larger patient series are needed to confirm these results.ed to confirm these results.

 Objective: This study aimed to examine whether there is a difference in the level of immune response against hepatitis A virus between patients with and without COVID-19 infection. Materials and Methods: Fifty patients with COVID-19 disease confirmed by PCR positivity who were followed in our clinic between 1 June 2020 and 1 September 2020 were enrolled in this cross-sectional, retrospective, single-center study. A total of 150 patients, who had similar demographic characteristics and were randomly selected among the patients who Anti HAV IgG levels were determined during their admission to our clinic in the last two years before the pandemic November 1, 2017-November 1, 2019 were taken as the control group. Anti-HAV IgG seropositivity rates and serum antibody titers were compared between these two groups. Results: The median age of the 200 cases was 48.5 25.-75.Quartiles43.0-59.0 years, 108 54 were male and 92 46 were female. One hundred, and forty-two of the cases were 60 years and above, but the proportion of the patients aged 60 and over in the patient groups was similar p0.105. Although anti-HAV IgG seropositivity rates in COVID-19 patients were similar to cases in the control group p0.062, anti-HAV IgG titers in COVID-19 cases were found to be significantly lower than in control patients p0.001. Anti-HAV IgG titers were found to be significantly lower in critical COVID-19 patients n7 compared to other COVID-19 patients n43, p0.049. In addition, it was observed that there was a significant and strong correlation between the anti-HAV IgG titer and the presence of critical COVID-19 disease η0.988. Conclusion: Although our results seem to support the thesis that the presence of HAV vaccine or previous HAV infection may be protective against COVID- 19 infection, especially in terms of preventing critical disease course, prospective studies with larger patient series are needed to confirm these results.ed to confirm these results.

 Objective: This study aimed to examine whether there is a difference in the level of immune response against hepatitis A virus between patients with and without COVID-19 infection. Materials and Methods: Fifty patients with COVID-19 disease confirmed by PCR positivity who were followed in our clinic between 1 June 2020 and 1 September 2020 were enrolled in this cross-sectional, retrospective, single-center study. A total of 150 patients, who had similar demographic characteristics and were randomly selected among the patients who Anti HAV IgG levels were determined during their admission to our clinic in the last two years before the pandemic November 1, 2017-November 1, 2019 were taken as the control group. Anti-HAV IgG seropositivity rates and serum antibody titers were compared between these two groups. Results: The median age of the 200 cases was 48.5 25.-75.Quartiles43.0-59.0 years, 108 54 were male and 92 46 were female. One hundred, and forty-two of the cases were 60 years and above, but the proportion of the patients aged 60 and over in the patient groups was similar p0.105. Although anti-HAV IgG seropositivity rates in COVID-19 patients were similar to cases in the control group p0.062, anti-HAV IgG titers in COVID-19 cases were found to be significantly lower than in control patients p0.001. Anti-HAV IgG titers were found to be significantly lower in critical COVID-19 patients n7 compared to other COVID-19 patients n43, p0.049. In addition, it was observed that there was a significant and strong correlation between the anti-HAV IgG titer and the presence of critical COVID-19 disease η0.988. Conclusion: Although our results seem to support the thesis that the presence of HAV vaccine or previous HAV infection may be protective against COVID- 19 infection, especially in terms of preventing critical disease course, prospective studies with larger patient series are needed to confirm these results.ed to confirm these results.

 Amaç: Bu çalışma ile COVID-19 enfeksiyonu olan ve olmayan olgular arasında Hepatit A virüsüne karşı kazanılmış immün yanıt düzeyi açısından fark bulunup bulunmadığının irdelenmesi amaçlanmıştır. Gereç ve Yöntemler: Bu retrospektif, kesitsel, tek merkez çalışmasına kliniğimizde 1 Haziran 2020-1 Eylül 2020 tarihleri arasında COVID-19 hastalığı PCR pozitifliği ile doğrulanmış nedeniyle takip edilmiş 50 olgu dahil edildi. Benzer demografik özelliklere sahip olan, salgın öncesindeki son iki yılda 1 Kasım 20171 Kasım 2019 kliniğimize başvuruları sırasında Anti HAV IgG düzeyleri belirlenmiş olgular arasından rastlantısal olarak seçilen toplam 150 olgu ise kontrol grubu olarak alındı. Bu iki grup arasında Anti-HAV IgG seropozitiflik oranları ile serum antikor titreleri karşılaştırıldı. Bulgular: Çalışmaya dahil edilen toplam 200 olgunun ortanca yaşı 48.5 IQR43.0-59.0 yıl olup, 108i 54 erkek, 92si 46 kadındı. Olguların 142si 71 60 yaş ve üzerinde idi, ancak hasta grupları içerisindeki 60 yaş ve üzeri olguların oranı benzerdi p0.105. COVID-19 olgularındaki Anti-HAV IgG seropozitifliği oranları kontrol grubundaki olgularla benzer olmakla birlikte p0.062, COVID-19 olgularındaki anti HAV IgG titrelerinin, kontrol olgularındakine göre anlamlı oranda daha düşük olduğu görüldü p0.001. Anti-HAV IgG titrelerinin kritik seyirli COVID-19 olgularında n7, diğer COVID-19 olgularına n43 göre anlamlı oranda daha düşük olduğu görüldü p0.049. Buna ek olarak anti-HAV titresi ile kritik COVID-19 hastalığı varlığı arasında anlamlı ve güçlü düzeyde bir ilişki olduğu η0.988 görüldü. Sonuç: Sonuçlarımız HAV aşısı veya geçirilmiş HAV enfeksiyonu varlığının COVID-19 enfeksiyonunda, özellikle kritik hastalık seyrinin önlenmesi açısından, koruyucu olabileceğini göstermektedir.

Makale detayları

Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study

Yazarlar:

Tayibe Bal | Hasibullah Yaqoobi | Yusuf Önlen | Mehmet Çabalak | Serdar Doğan

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 2, pp.16-21

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001295731

pISSN:

1303-6610

anti-HAV IgG antibody titer

COVID-19

hepatitis A vaccine.Anti-HAV IgG Antikor Titresi

COVID-19

Hepatit A Aşısı.

Sayı

Makale detayları

Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study

Yazarlar: Tayibe Bal | Hasibullah Yaqoobi | Yusuf Önlen | Mehmet Çabalak | Serdar Doğan

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 2, pp.16-21

Belge Tipi: Makale

Yayın Tarihi: 12/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001295731

pISSN: 1303-6610

anti-HAV IgG antibody titer

COVID-19

hepatitis A vaccine.Anti-HAV IgG Antikor Titresi

COVID-19

Hepatit A Aşısı.

Sayı

Yazarlar:

Tayibe Bal | Hasibullah Yaqoobi | Yusuf Önlen | Mehmet Çabalak | Serdar Doğan

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 2, pp.16-21

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001295731

pISSN:

1303-6610